Depemokimab significantly reduces asthma exacerbations, showing similar efficacy in both controlled and uncontrolled asthma patients. The study included patients with eosinophilic asthma using medium- ...

Please provide your email address to receive an email when new articles are posted on . Asthma control and quality-of-life scores improved over 16 weeks in a weight management program vs. usual care.

In the VOYAGE trial, dupilumab (Dupixent) significantly reduced asthma exacerbations and improved lung function and asthma control in children (ages 6 to 11 years) with uncontrolled, ...

Adults with moderate to severe asthma with uncontrolled symptoms had significantly improved asthma control with daily oral ...

The digital asthma self-management program significantly improved symptom control, especially for those with uncontrolled asthma, showing a 2.8-point Asthma Control Test score difference over usual ...

Dupilumab reduced airway inflammation and mucus burden and enhanced airway volume and flow, which led to better lung function and improved asthma control in patients with moderate to severe type 2 ...

Omalizumab therapy was linked to improved inflammatory biomarkers and symptom scores after 16 weeks in patients with severe allergic asthma.

Cladosporium is a genus of ubiquitous environmental fungi that has been reported to induce asthma and colonize the airways of both healthy and asthmatic individuals. A study presented at the CHEST ...

Dupilumab significantly outperformed omalizumab in reducing the size of nasal polyps and improving sense of smell in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP) and coexisting ...